BJ ENT WATER
00371
PCCW
00008
CHINA TELECOM
00728
U-PRESID CHINA
00220
CHINA UNICOM
00762
HK Stock MarketDetailed Quotes
09877 JENSCARE-B
- 4.210
- +0.040+0.96%
Trading Feb 18 14:19 CST
1.76BMarket Cap-5.38P/E (TTM)
4.260High4.100Low137.20KVolume4.110Open4.170Pre Close574.16KTurnover0.04%Turnover RatioLossP/E (Static)417.17MShares13.70052wk High1.48P/B1.31BFloat Cap1.40052wk Low--Dividend TTM310.31MShs Float94.700Historical High--Dividend LFY3.84%Amplitude1.400Historical Low4.184Avg Price200Lot Size--Div YieldTTM--Div Yield LFY
JENSCARE-B News
AI hotspots continue to boost! Most Medical stocks in Hong Kong strengthen, with Micro-invasion Siasun Robot&Automation rising over 20%.
How does Sister Wood perceive this hot topic of AI Medical? What positive impacts will the emergence of DeepSeek bring to the medical field?
Hong Kong stocks fluctuation丨Jianshi Technology appoints a new CEO, Pan Fei, today the stock price rises nearly 5%.
Gelonghui January 16 | Jianshi Technology-B (9877.HK) closed up 4.9% today, at HKD 4.13. The company announced last night that in order to further promote the group's Global Strategy, comprehensively deepen and accelerate the Global commercialization process, Mr. Pan Fei has been appointed as the Chief Executive Officer nominated by Mr. Lu Shiwun, and this appointment was unanimously approved by the company's nomination committee and Board of Directors.
Jenscare Scientific: Pan Fei Appointed as CEO
Jianshi Technology-B (09877.HK) has appointed Pan Fei as the Chief Executive Officer.
Gelonghui, January 15 | Health Technology-B (09877.HK) announced that to further promote the Group's Global Strategy and comprehensively deepen and accelerate the Global commercialization process, Mr. Lu Shiwun has informed the company that he will resign from the position of Chief Executive Officer and has nominated Mr. Pan Fei as the Chief Executive Officer. The appointment of the Chief Executive Officer has been unanimously approved by the company's nomination committee and Board of Directors on January 15, 2025.
Express News | China International Capital Corporation: The medical instruments Sector is expected to benefit from product upgrades and overseas exports in 2025.
Jianshi Technology-B (09877.HK) received a Shareholding of 5.4036 million shares listed in Hong Kong from Trinity Elite I International Limited and its affiliates, valued at approximately 17.4515 million Hong Kong dollars.
On December 12, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on December 12, Trinity Elite I International Limited increased its shareholding in $Kangshengtai Technology-B(09877.HK)$ by 5,403,600 shares of Listed in Hong Kong at an average price of HK$3.2296 per share on December 9, which is worth approximately HK$17.4515 million. After the increase, Trinity Elite I International Limited's latest shareholding number is 30,091,400 shares, with a good position ratio of 7.
Healthcare technology company B(09877.HK) received a total of 2.2442 million shares of H股 shares from Trinity Elite I International Limited and its affiliates, worth approximately 6.0712 million Hong Kong dollars.
Reported on November 6, according to the documents disclosed by the Hong Kong Stock Exchange on November 6, Trinity Elite I International Limited increased its shareholding in Health technology - B (09877.HK) by an average price of HK$2.7053 per share on November 1, acquiring 2.2442 million H shares, worth approximately HK$6.0712 million. After the increase, Trinity Elite I International Limited's latest number of shares held is 23.693 million shares, and the favorable warehouse ratio increased from 6.91% to
The one-year clinical data performed excellently, Health World Technology - B (09877) actively explores overseas markets, accelerating the commercialization potential.
As a core l product highly anticipated by the market, LuX-Valve Plus has many highlights in both market prospects and technical value.
The One-Year Outcome of LuX-Valve Plus TRAVEL II Study Was Officially Released at TCT 2024
Genesystechnology - B (09877.HK): LuX-Valve Plus TRAVEL II one-year clinical follow-up results will be released at the 2024 Catheter Cardiovascular Scientific Conference in Washington, USA.
Galunhui October 31st | Health World Technology-B (09877.HK) announced, recently, the one-year clinical follow-up results of LuX-Valve Plus transvascular tricuspid valve interventional replacement system multi-center clinical trial (TRAVEL II) were released at the Transcatheter Cardiovascular Therapeutics Conference (TCT 2024) in the usa. TRAVEL II is mainly used to evaluate the long-term safety and efficacy of LuX-Valve Plus in patients with severe tricuspid regurgitation. The TRAVEL II clinical trial included a total of 96 patients from 15 centers in china. This time clinical
Hong Kong stock concept tracking | Medical devices trade-in program attracts institutional attention, clear trend of market recovery.
"Trade-in" is accelerating in the field of medical devices, and various provinces are intensively issuing "feasibility announcements", "project approval announcements" and "tender procurement notices", injecting a dose of "cardiotonic" into the market.
Health world technology-B (09877.HK) received Trinity Elite I International Limited and its associates to increase the shareholding of 2.4762 million H shares, worth approximately 6.3336 million Hong Kong dollars.
On October 23, according to the documents disclosed by the Hong Kong Stock Exchange on October 23, Trinity Elite I International Limited increased its shareholding in $ Health Technology - B (09877.HK) $ by an average price of HK$ 2.5578 per share on October 18, amounting to 2.4762 million H shares, worth approximately HK$ 6.3336 million. After the increase in shareholding, Trinity Elite I International Limited's latest number of shareholdings is 19.9042 million shares, with the warehouse ratio increasing from 5.6
Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space
Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.
There is no limit on price fluctuation, new stocks are being speculated! The pioneer of ultrasound submits an application for registration on the gem.
Cumulative dividends exceed 0.3 billion over 4 years.
JENSCARE-B: 2024 Interim Report
The Stock Exchange of Shanghai and the Stock Exchange of Shenzhen: 33 shares will be included in the Hong Kong Stock Connect symbol from today.
The Shanghai Stock Exchange and Shenzhen Stock Exchange have announced that 33 stocks have been included in the list of Hong Kong stocks eligible for trading through the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect starting today.
Express News | China Securities Co.,Ltd. recommends focusing on investment opportunities in the medical device sector, and focusing on the direction and individual stocks with strong performance certainty.
Jenscare Scientific's H1 Loss Narrows by 42%; Shares Fall 10%
Healthcare Technology-B (9877.HK) financial report analysis: Overseas clinical continuous breakthroughs, stable funds helping to build momentum.
The innovative development of the medical instruments industry has once again received a major bullish signal. Recently, the Third Plenary Session of the Central Committee clearly proposed to "improve the mechanism to support the development of medical instruments", injecting new momentum into the innovation and research of medical instruments, and also indicating the direction for the rapid development of the industry. The intensified support at the top level design means that these manufacturers will receive more resources and policy inclinations, injecting new impetus into the innovation and research of medical instruments. From an investment logic perspective, the market's attention to the medical instruments industry has long shifted from simple domestic substitution to a dual consideration of innovative capabilities and market competitiveness. Investors are increasingly focusing on those that can provide disruptive
The performance of Jian Shi technology (09877.HK) narrowed its losses to 0.102 billion RMB in the first half of the year.
Health World Technology-B (09877.HK) announced its interim performance as of the end of June this year, with other income and gains of 16.95 million RMB (all below), down 50.2% year-on-year. Losses narrowed to 0.102 billion RMB, compared to a loss of 0.176 billion RMB in the same period last year; loss per share was 25 cents. No dividend will be distributed.
Trending Stocks
HK Dividend Stocks HK Dividend Stocks
Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data. Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data.
